Can we increase the speed and efficacy of antidepressant treatments? Part II. Glutamatergic and RNA interference strategies.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  European Neuropsychopharmacology

• Publication date

  2018-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.euroneuro.2018.01.005PMID 29525411
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Temporal Dynamics of Antidepressant Ketamine Effects on Glutamine Cycling Follow Regional Fingerprints of AMPA and NMDA Receptor Densities

  2017cited by this paper
• Glial GLT-1 blockade in infralimbic cortex as a new strategy to evoke rapid antidepressant-like effects in rats

  2017influential reference
• Diagnostic and therapeutic potential of microRNAs in neuropsychiatric disorders: Past, present, and future

  2017cited by this paper
• Ketamine and pharmacological imaging: use of functional magnetic resonance imaging to evaluate mechanisms of action

  2017cited by this paper
• Epigenetic Basis of Mental Illness

  2016cited by this paper
• NMDAR inhibition-independent antidepressant actions of ketamine metabolites

  2016influential reference
• Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants

  2016influential reference
• The Antidepressant Effects of an mGlu2/3 Receptor Antagonist and Ketamine Require AMPA Receptor Stimulation in the mPFC and Subsequent Activation of the 5-HT Neurons in the DRN

  2016cited by this paper
• Ketamine-induced brain activation in awake female nonhuman primates: a translational functional imaging model

  2016cited by this paper
• KETAMINE'S MECHANISM OF ACTION: A PATH TO RAPID‐ACTING ANTIDEPRESSANTS

  2016influential reference
• Two cellular hypotheses explaining the initiation of ketamine's antidepressant actions: Direct inhibition and disinhibition.

  2016influential reference
• The effects of low‐dose ketamine on the prefrontal cortex and amygdala in treatment‐resistant depression: A randomized controlled study

  2016cited by this paper
• Activation of AMPA Receptors Mediates the Antidepressant Action of Deep Brain Stimulation of the Infralimbic Prefrontal Cortex.

  2016cited by this paper
• BDNF - a key transducer of antidepressant effects.

  2016cited by this paper
• Oral ketamine for the treatment of pain and treatment-resistant depression†.

  2016cited by this paper
• Species-conserved reconfigurations of brain network topology induced by ketamine

  2016cited by this paper
• Identification of Differential MicroRNAs in Cerebrospinal Fluid and Serum of Patients with Major Depressive Disorder

  2015cited by this paper
• MicroRNAs: Small molecules with big roles in neurodevelopment and diseases

  2015cited by this paper
• Temporal Dynamics of Antidepressant Ketamine Effects On Glutamine Cycling Follow Regional Fingerprints of Ampa and Nmda Receptor Densities

  2015cited by this paper
• Increased Signaling via Adenosine A1 Receptors, Sleep Deprivation, Imipramine, and Ketamine Inhibit Depressive-like Behavior via Induction of Homer1a.

  2015cited by this paper
• Preclinical and clinical development of siRNA-based therapeutics.

  2015cited by this paper
• MicroRNA biogenesis pathways in cancer

  2015cited by this paper
• Ketamine produces antidepressant-like effects through phosphorylation-dependent nuclear export of histone deacetylase 5 (HDAC5) in rats

  2015cited by this paper
• An updated role of microRNA-124 in central nervous system disorders: a review

  2015cited by this paper
• Acute ketamine challenge increases resting state prefrontal-hippocampal connectivity in both humans and rats

  2015cited by this paper
• Therapeutic antidepressant potential of a conjugated siRNA silencing the serotonin transporter after intranasal administration

  2015influential reference
• Optogenetic stimulation of infralimbic PFC reproduces ketamine’s rapid and sustained antidepressant actions

  2015influential reference
• Antidepressant actions of ketamine: from molecular mechanisms to clinical practice.

  2015cited by this paper
• Ketamine Strengthens CRF-Activated Amygdala Inputs to Basal Dendrites in mPFC Layer V Pyramidal Cells in the Prelimbic but not Infralimbic Subregion, A Key Suppressor of Stress Responses

  2015cited by this paper
• Reduced density of glutamine synthetase immunoreactive astrocytes in different cortical areas in major depression but not in bipolar I disorder

  2015cited by this paper
• Circulating microRNA-144-5p is associated with depressive disorders

  2015cited by this paper
• The RNA-centred view of the synapse: non-coding RNAs and synaptic plasticity

  2014cited by this paper
• Mice Lacking NMDA Receptors in Parvalbumin Neurons Display Normal Depression-Related Behavior and Response to Antidepressant Action of NMDAR Antagonists

  2014cited by this paper
• Chemical modifications on siRNAs avoid Toll-like-receptor-mediated activation of the hepatic immune system in vivo and in vitro.

  2014cited by this paper
• D-serine plasma concentration is a potential biomarker of (R,S)-ketamine antidepressant response in subjects with treatment-resistant depression

  2014cited by this paper
• The Role of GluN2A and GluN2B Subunits on the Effects of NMDA Receptor Antagonists in Modeling Schizophrenia and Treating Refractory Depression

  2014influential reference
• BDNF Release Is Required for the Behavioral Actions of Ketamine

  2014influential reference
• MicroRNA Expression Profile and Functional Analysis Reveal that miR-206 is a Critical Novel Gene for the Expression of BDNF Induced by Ketamine

  2014cited by this paper
• Virus-Mediated shRNA Knockdown of Prodynorphin in the Rat Nucleus Accumbens Attenuates Depression-Like Behavior and Cocaine Locomotor Sensitization

  2014cited by this paper
• Calcineurin downregulation in the amygdala is sufficient to induce anxiety-like and depression-like behaviors in C57BL/6J male mice.

  2014cited by this paper
• Enhancing ketamine translational pharmacology via receptor occupancy normalization.

  2014cited by this paper
• miR-1202: A Primate Specific and Brain Enriched miRNA Involved in Major Depression and Antidepressant Treatment

  2014cited by this paper
• Novel therapeutic strategies in major depression: focus on RNAi and ketamine.

  2014cited by this paper
• MicroRNA 135 is essential for chronic stress resiliency, antidepressant efficacy, and intact serotonergic activity.

  2014cited by this paper
• Phencyclidine inhibits the activity of thalamic reticular gamma-aminobutyric acidergic neurons in rat brain.

  2014cited by this paper
• A pilot study of plasma metabolomic patterns from patients treated with ketamine for bipolar depression: evidence for a response‐related difference in mitochondrial networks

  2014cited by this paper
• Human genetic variation and its effect on miRNA biogenesis, activity and function.

  2014cited by this paper
• R (-)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine.

  2014cited by this paper
• Epigenetic signaling in psychiatric disorders.

  2014cited by this paper
• Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.

  2013cited by this paper
• Subanaesthetic ketamine treatment alters prefrontal cortex connectivity with thalamus and ascending subcortical systems.

  2013cited by this paper
• Epigenetics of the Depressed Brain: Role of Histone Acetylation and Methylation

  2013cited by this paper
• GSK-3 Inhibition Potentiates the Synaptogenic and Antidepressant-Like Effects of Subthreshold Doses of Ketamine

  2013cited by this paper
• Environmental and pharmacological modulations of cellular plasticity: role in the pathophysiology and treatment of depression.

  2013cited by this paper
• RNA interference‐mediated phosphodiesterase 4D splice variants knock‐down in the prefrontal cortex produces antidepressant‐like and cognition‐enhancing effects

  2013cited by this paper
• Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR

  2013cited by this paper
• Cholinergic signaling in the hippocampus regulates social stress resilience and anxiety- and depression-like behavior

  2013cited by this paper
• RNAi-mediated serotonin transporter suppression rapidly increases serotonergic neurotransmission and hippocampal neurogenesis

  2013influential reference
• Acute Suppression of Spontaneous Neurotransmission Drives Synaptic Potentiation

  2013cited by this paper
• GluN2B Antagonism Affects Interneurons and Leads to Immediate and Persistent Changes in Synaptic Plasticity, Oscillations, and Behavior

  2013cited by this paper
• A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression.

  2013cited by this paper
• Ketamine Pharmacology: An Update (Pharmacodynamics and Molecular Aspects, Recent Findings)

  2013influential reference
• ¹H-[¹³C]-nuclear magnetic resonance spectroscopy measures of ketamine's effect on amino acid neurotransmitter metabolism.

  2012cited by this paper
• Modulation of medial prefrontal cortical activity using in vivo recordings and optogenetics

  2012cited by this paper
• A prefrontal cortex–brainstem neuronal projection that controls response to behavioural challenge

  2012cited by this paper
• Cell-type-based analysis of microRNA profiles in the mouse brain.

  2012cited by this paper
• Ketamine Decreases Resting State Functional Network Connectivity in Healthy Subjects: Implications for Antidepressant Drug Action

  2012cited by this paper
• Abnormal Hippocampal BDNF and miR-16 Expression Is Associated with Depression-Like Behaviors Induced by Stress during Early Life

  2012cited by this paper
• Selective siRNA-mediated suppression of 5-HT1A autoreceptors evokes strong anti-depressant-like effects

  2012influential reference
• Acute 5-HT1A autoreceptor knockdown increases antidepressant responses and serotonin release in stressful conditions

  2012influential reference
• Preclinical and clinical characterization of the selective 5‐HT1A receptor antagonist DU‐125530 for antidepressant treatment

  2012influential reference
• mTOR activation is required for the antidepressant effects of mGluR₂/₃ blockade.

  2012cited by this paper
• Raphe-mediated signals control the hippocampal response to SRI antidepressants via miR-16

  2011cited by this paper
• A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department.

  2011cited by this paper
• Frontocingulate Dysfunction in Depression: Toward Biomarkers of Treatment Response

  2011cited by this paper
• NMDA Receptor Blockade at Rest Triggers Rapid Behavioural Antidepressant Responses

  2011influential reference
• TASK-3 as a potential antidepressant target.

  2011influential reference
• Electroconvulsive therapy: a novel hypothesis for the involvement of purinergic signalling

  2011influential reference
• Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure.

  2011influential reference
• Activation of thalamocortical networks by the N-methyl-D-aspartate receptor antagonist phencyclidine: reversal by clozapine.

  2011influential reference
• Neurochemical and behavioural effects of acute and chronic memantine administration in rats: Further support for NMDA as a new pharmacological target for the treatment of depression?

  2010cited by this paper
• Anterior Cingulate Desynchronization and Functional Connectivity with the Amygdala During a Working Memory Task Predict Rapid Antidepressant Response to Ketamine

  2010cited by this paper
• MiR-16 Targets the Serotonin Transporter: A New Facet for Adaptive Responses to Antidepressants

  2010cited by this paper
• Antidepressant Effect of Optogenetic Stimulation of the Medial Prefrontal Cortex

  2010cited by this paper
• mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists

  2010cited by this paper
• Recent progress in chemically modified siRNAs.

  2010cited by this paper
• Metabotropic glutamate receptor 7: at the interface of cognition and emotion.

  2010cited by this paper
• Nanomedicine based approaches for the delivery of siRNA in cancer

  2010cited by this paper
• The widespread regulation of microRNA biogenesis, function and decay

  2010cited by this paper
• The neurobiology of psychedelic drugs: implications for the treatment of mood disorders

  2010influential reference
• Antidepressant-like effects of medial prefrontal cortex deep brain stimulation in rats.

  2010cited by this paper
• Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.

  2010cited by this paper
• miR-124 regulates adult neurogenesis in the SVZ stem cell niche

  2009cited by this paper
• A Defined Network of Fast-Spiking Interneurons in Orbitofrontal Cortex: Responses to Behavioral Contingencies and Ketamine Administration

  2009cited by this paper
• Glutamate Based Antidepressants : 20 Years On

  2009cited by this paper
• Evidence for Selective microRNAs and Their Effectors as Common Long-Term Targets for the Actions of Mood Stabilizers

  2009cited by this paper
• Comparison of racemic ketamine and S-ketamine in treatment-resistant major depression: Report of two cases

  2009influential reference
• Glutamate-based antidepressants: 20 years on.

  2009cited by this paper
• Kappa-opioid ligands in the study and treatment of mood disorders.

  2009cited by this paper
• Knockdown of brain-derived neurotrophic factor in specific brain sites precipitates behaviors associated with depression and reduces neurogenesis

  2009cited by this paper

• New Advances in the Pharmacology and Toxicology of Lithium: A Neurobiologically Oriented Overview

  2024cites this paper
• The pharmacological management of treatment-resistant depression: what does the future hold?

  2023cites this paper
• A Selective Review of the Excitatory-Inhibitory Imbalance in Schizophrenia: Underlying Biology, Genetics, Microcircuits, and Symptoms

  2021cites this paper
• Oligonucleotides as therapeutic tools for brain disorders: Focus on major depressive disorder and Parkinson's disease.

  2021cites this paper
• The miRNome of Depression

  2021cites this paper
• How the enriched get richer? Experience-dependent modulation of microRNAs and the therapeutic effects of environmental enrichment.

  2020cites this paper
• Serotonin in panic and anxiety disorders

  2020cites this paper
• Antidepressant-like effects of ketamine in a mouse model of serotonergic dysfunction.

  2020cites this paper
• Exploring the impact of trauma type and extent of exposure on posttraumatic alterations in 5-HT1A expression

  2020cites this paper
• Epilepsy miRNA Profile Depends on the Age of Onset in Humans and Rats

  2020cites this paper
• Genetic, epigenetic and posttranscriptional mechanisms for treatment of major depression: the 5-HT1A receptor gene as a paradigm

  2019cites this paper
• Antidepressant actions of ketamine. Nobel action mechanisms in the search of antidepressant drugs

  2019cites this paper
• Modulation of thalamo-cortical activity by the NMDA receptor antagonists ketamine and phencyclidine in the awake freely-moving rat.

  2019cites this paper
• Regionally selective knockdown of astroglial glutamate transporters in infralimbic cortex induces a depressive phenotype in mice

  2019cites this paper
• Selective Knockdown of TASK3 Potassium Channel in Monoamine Neurons: a New Therapeutic Approach for Depression

  2018cites this paper
• Preparation and Characterization of Functionalized Graphene Oxide Carrier for siRNA Delivery

  2018cites this paper
• Somato-Dendritic Regulation of Raphe Serotonin Neurons; A Key to Antidepressant Action

  2018cites this paper